Day: July 13, 2012

Northwest Pharmacy – www.NorthWestPharmacy.com

1 Comment


TO: CustomerService@NorthWestPharmacy.com
FROM: United States Food and Drug Administration
Center for Drug Evaluation and Research
Office of Compliance
Office of Drug Security, Integrity and Recalls
Division of Supply Chain Integrity
RE: Internet Marketing of an Unapproved and Misbranded Drug
DATE: May 24, 2012

WARNING LETTER

The United States Food and Drug Administration (FDA) reviewed your website, www.NorthWestPharmacy.com, on January 4, 2012 and has determined that your website offers products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the website offers an unapproved and misbranded new drug for sale in violation of sections 502(f) and 505(a) of the FD&C Act [21 U.S.C. §§ 352(f) and 355(a)], which are prohibited acts under sections 301(a) and 301(d) of the FD&C Act [21 U.S.C. §§ 331(a) and 331(d)], respectively. We request that you immediately cease marketing violative drug products to United States consumers.

Unapproved New Drug

Alitretinoin, trade name, Toctino, is offered for sale on your website “to treat severe long-term eczema that affects the hands … for patients who have not found success using other corticosteroid treatments.” Based on this claim, Toctino appears to be a drug within the meaning of section 201(g) of the FD&C Act [21 U.S.C. §321(g)] because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or it is intended to affect the structure or function of the body. Moreover, Toctino appears to be a new drug within the meaning of section 201 (p) of the FD&C Act [21 U.S.C. §321(p)] because it is not generally recognized as safe and effective for its labeled use. Although Toctino is approved in Canada, no approved application pursuant to section 505 of the FD&C Act [21 U.S.C. §355] is in effect for this product. Accordingly, its introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&C Act [21 U.S.C. §355(a)] and is prohibited under section 301(d) of the FD&C Act [21 U.S.C. §331(d)].

Misbranded Drug

Alitretinoin is a retinoid that is potentially dangerous when orally administered due to its teratogenicity. Because of this potential toxicity, its Canadian labeling states that it should be prescribed only by physicians knowledgeable in the use of systemic retinoids and who understand the risks of teratogenicity in females of childbearing potential. In addition, these females are required to have pregnancy tests before, at regular intervals during, and after discontinuation of alitretinoin therapy to exclude pregnancy. Because Toctino is unapproved in the United States, these safety controls are bypassed when alitretinoin is purchased over the Internet by customers in the United States without consultation with and a valid prescription from a physician.

This places American patients who use the drug at risk for adverse effects. Thus, Toctino offered for sale on your website is misbranded within the meaning of section 502(f)(1) of the FD&C Act [21 U.S.C. §321(f)(1)] in that the labeling for Toctino fails to bear adequate directions for use. The introduction or delivery for introduction into interstate commerce of a misbranded drug product is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. §331(a)].

FDA is taking action against your firm because of the inherent risk in buying unapproved and misbranded new drugs. Unapproved new drugs may not have the same assurance of safety, efficacy, and quality as drugs subject to FDA oversight, and such drugs have been found to be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.

FDA- regulated drugs offer protections that include rigorous scientific standards for new drug approval, labeling review for accuracy and completeness, and manufacturing procedures and testing performed under closely controlled conditions at FDA-registered and inspected facilities.

In addition, pharmacies and wholesalers who sell or distribute prescription drugs in the U.S. are licensed by the states. Unapproved new drugs delivered to the American public may not be safe and effective.

This letter is not intended to identify all of the ways in which your activities might be in violation of law. It is your responsibility to ensure that all products marketed by your firm are in compliance with FD&C Act and its implementing regulations. You should take prompt action to correct the violations noted above. Failure to correct these violations promptly may result in FDA regulatory action, including but not limited to, seizure or injunction, without further notice.

Please notify this office in writing within 15 working days of receipt of this letter of any steps you have taken or will take to correct the noted violations and to prevent their recurrence. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response should be sent to DrugSupplyChainintegrity@fda.hhs.gov.

Please direct any inquiries concerning this letter to Leigh Verbois, Acting Deputy Director for the Division of Supply Chain Integrity at the above address.

Sincerely,

/s/

Thomas Christl, Office Director (Acting)
Office of Drug Security, Integrity and Recalls
Office of Compliance

Northwest Pharmacy – www.NorthWestPharmacy.com

1 Comment


TO: CustomerService@NorthWestPharmacy.com
FROM: United States Food and Drug Administration
Center for Drug Evaluation and Research
Office of Compliance
Office of Drug Security, Integrity and Recalls
Division of Supply Chain Integrity
RE: Internet Marketing of an Unapproved and Misbranded Drug
DATE: May 24, 2012

WARNING LETTER

The United States Food and Drug Administration (FDA) reviewed your website, www.NorthWestPharmacy.com, on January 4, 2012 and has determined that your website offers products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the website offers an unapproved and misbranded new drug for sale in violation of sections 502(f) and 505(a) of the FD&C Act [21 U.S.C. §§ 352(f) and 355(a)], which are prohibited acts under sections 301(a) and 301(d) of the FD&C Act [21 U.S.C. §§ 331(a) and 331(d)], respectively. We request that you immediately cease marketing violative drug products to United States consumers.

Unapproved New Drug

Alitretinoin, trade name, Toctino, is offered for sale on your website “to treat severe long-term eczema that affects the hands … for patients who have not found success using other corticosteroid treatments.” Based on this claim, Toctino appears to be a drug within the meaning of section 201(g) of the FD&C Act [21 U.S.C. §321(g)] because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or it is intended to affect the structure or function of the body. Moreover, Toctino appears to be a new drug within the meaning of section 201 (p) of the FD&C Act [21 U.S.C. §321(p)] because it is not generally recognized as safe and effective for its labeled use. Although Toctino is approved in Canada, no approved application pursuant to section 505 of the FD&C Act [21 U.S.C. §355] is in effect for this product. Accordingly, its introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&C Act [21 U.S.C. §355(a)] and is prohibited under section 301(d) of the FD&C Act [21 U.S.C. §331(d)].

Misbranded Drug

Alitretinoin is a retinoid that is potentially dangerous when orally administered due to its teratogenicity. Because of this potential toxicity, its Canadian labeling states that it should be prescribed only by physicians knowledgeable in the use of systemic retinoids and who understand the risks of teratogenicity in females of childbearing potential. In addition, these females are required to have pregnancy tests before, at regular intervals during, and after discontinuation of alitretinoin therapy to exclude pregnancy. Because Toctino is unapproved in the United States, these safety controls are bypassed when alitretinoin is purchased over the Internet by customers in the United States without consultation with and a valid prescription from a physician. This places American patients who use the drug at risk for adverse effects. Thus, Toctino offered for sale on your website is misbranded within the meaning of section 502(f)(1) of the FD&C Act [21 U.S.C. §321(f)(1)] in that the labeling for Toctino fails to bear adequate directions for use. The introduction or delivery for introduction into interstate commerce of a misbranded drug product is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. §331(a)].

FDA is taking action against your firm because of the inherent risk in buying unapproved and misbranded new drugs. Unapproved new drugs may not have the same assurance of safety, efficacy, and quality as drugs subject to FDA oversight, and such drugs have been found to be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.

FDA- regulated drugs offer protections that include rigorous scientific standards for new drug approval, labeling review for accuracy and completeness, and manufacturing procedures and testing performed under closely controlled conditions at FDA-registered and inspected facilities.

In addition, pharmacies and wholesalers who sell or distribute prescription drugs in the U.S. are licensed by the states. Unapproved new drugs delivered to the American public may not be safe and effective.

This letter is not intended to identify all of the ways in which your activities might be in violation of law. It is your responsibility to ensure that all products marketed by your firm are in compliance with FD&C Act and its implementing regulations. You should take prompt action to correct the violations noted above. Failure to correct these violations promptly may result in FDA regulatory action, including but not limited to, seizure or injunction, without further notice.

Please notify this office in writing within 15 working days of receipt of this letter of any steps you have taken or will take to correct the noted violations and to prevent their recurrence. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response should be sent to DrugSupplyChainintegrity@fda.hhs.gov.

Please direct any inquiries concerning this letter to Leigh Verbois, Acting Deputy Director for the Division of Supply Chain Integrity at the above address.

Sincerely,

/s/

Thomas Christl, Office Director (Acting)
Office of Drug Security, Integrity and Recalls
Office of Compliance

www.cigarettesbuyonline.com

Leave a comment

VIA UPS

JUN 15, 2012

NameCheap, Inc
11400 W. Olympic Blvd., Suite 200
Los Angeles, CA 90064

WARNING LETTER

The Center for Tobacco Products of the Food and Drug Administration (FDA) recently reviewed the website http://www.cigarettesbuyonline.com, and determined that the cigarette products listed are offered for sale to U.S. customers. Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C.§ 321(rr)), as amended by the Family Smoking Prevention and Tobacco Control Act, these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including cigarettes, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)).

FDA has determined that several of your products are adulterated under section 902(8) of the FD&C Act (21 U.S.C. § 387b(8)) because you promote them as modified risk tobacco products without an FDA order in effect that permits such promotion. Additionally, FDA has determined that your “Aroma Rich Apple” and “Aroma Rich Rum Cherry” cigarettes are adulterated under section 902(5) of the FD&C Act (21 U.S.C. § 387b(5)) or misbranded under section 903(a)(1) of the FD&C Act (21 U.S.C. § 387c(a)(1)). You can find the FD&C Act through links on FDA’s homepage at http://www.fda.gov.

You describe products that you offer for sale on the website http://www.cigarettesbuyonline.com as being “Light” or “Ultra-Light” by referring to them as such in product advertising. Specifically, our review of the website revealed that you offer for sale the following cigarettes described as “Lights”: Bond Special Selection, Camel Blue, Chesterfield Classic Blue, Davidoff Gold, Dunhill Fine Cut Dark Blue, Kent Blue Futura No. 8, Lucky Strike Original Silver, Marlboro Gold, Parliament Aqua Blue, Winston Blue, Winston Super Slims Blue 1 DO’s, Magna Balanced Blue, More Balanced Blue, Pall Mall Blue, Sobranie Blue, Sobranie White Russian, and Viceroy Blue. Our review of the website revealed that you offer for sale the following cigarettes described as “Ultra-Lights”: Bond Fine Selection, Camel Silver, Chesterfield Classic Bronze, Davidoff Blue, Dunhill Fine Cut Azure, Kent Silver Neo No. 4, L&M Silver Label, Parliament Silver Blue, Vogue Super Slims Lilas 100s, Winston Silver, Camel Black Mini, Marlboro Silver, More Subtle Silver, Pall Mall Azure, Sobranie Gold, and Viceroy Silver.

A tobacco product with a label, labeling, or advertising that uses the descriptor “light,” “mild,” or “low,” or a similar descriptor, is a “modified risk tobacco product” under section 911(b)(2)(A)(ii) of the FD&C Act (21 U.S.C. § 387k(b)(2)(A)(ii)). Under section 911(a) of the FD&C Act (21 U.S.C. § 387k(a)), no person may introduce or deliver for introduction into interstate commerce any modified risk tobacco product without an FDA order in effect under section 911(g) of the FD&C Act 21 U.S.C. § 387k(g)). A product that is in violation of section 911(a) of the FD&C Act (21 U.S.C.§ 387k(a)) is adulterated under section 902(8) of the FD&C Act (21 U.S.C. § 387b(8)). Because the website uses the descriptor “light” or similar descriptors for the above-listed products, the products are modified risk tobacco products. Because these products are offered for sale to U.S. customers without an appropriate FDA order in effect under section 911(g) of the FD&C Act (21 U.S.C. § 387k(g)), these products are adulterated under section 902(8) of the FD&C Act (21 U.S.C. § 387b(8)).

Additionally, our review of the website http://www.cigarettesbuyonline.com revealed that you offer for sale the following cigarettes: Aroma Rich Apple and Aroma Rich Rum Cherry, which are purported to contain an artificial or natural flavor that is a characterizing flavor of the product. Section 907(a)(1)(A) of the FD&C Act (21 U.S.C. § 387g(a)(1)(A)) provides:

[A] cigarette or any of its component parts (including the tobacco, filter, or paper) shall not contain, as a constituent (including a smoke constituent) or additive, an artificial or natural flavor (other than tobacco or menthol) or an herb or spice … that is a characterizing flavor of the tobacco product or tobacco smoke.

As of September 22, 2009, cigarettes marketed and sold in the United States in violation of this provision are adulterated under section 902(5) of the FD&C Act (21 U.S.C. § 387b(5)). Thus, your flavored cigarettes are adulterated.

If, however, these cigarettes do not contain a characterizing flavor, they are misbranded under section 903(a)(1) of the FD&C Act (21 U.S.C. § 387c(a)(1)) as their labeling is false and misleading because it makes the representation that the products contain apple, or rum cherry as characterizing flavors of the tobacco products.

You should immediately correct the violations stated above and take any necessary actions to bring your tobacco products into compliance with the FD&C Act. The violations discussed in this letter do not necessarily constitute an exhaustive list, and it is your responsibility to ensure that your tobacco products on this website, or any other websites you own, operate, and/or control, comply with the applicable provisions of the FD&C Act. Failure to ensure full compliance with the FD&C Act may result in FDA initiating further action without notice, including, but not limited to, civil money penalties, no-tobacco-sale orders, criminal prosecution, seizure, and/or injunction. Please note that adulterated and misbranded tobacco products offered for importation into the United States are subject to detention and refusal of admission.

Please submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions, including the dates on which you discontinued the violative promotion, advertising, sale, and/or distribution of these tobacco products.

Please note your reference number, RW1200014, in your response and direct your response to the following address:

PAL-WL Response, Office of Compliance and Enforcement
FDA Center for Tobacco Products
9200 Corporate Boulevard
c/o Document Control Center
Rockville, Maryland 20850.

If you have any questions about the content of this letter, please contact Ele lbarra-Pratt at (301) 796-9235 or via email at Elenita.lbarraPratt@fda.hhs.gov.

Sincerely,

/S/

Ann Simoneau, J.D.
Director
Office of Compliance and Enforcement
Center for Tobacco Products

VIA Fascimile and Electronic mail
Cc:
NameCheap, Inc
Fax:(661) 310-2107

81dfb5bde97c46efb846c8558fada1d2.protect@whoisguard.com
support@namecheap.com

www.buycheaptobacco.net

Leave a comment

JUNE 15, 2012

VIA UPS                                                   
Protected Domain Services                  
191 University Boulevard, Unit #384
Denver, CO 80206
 
WARNING LETTER
The Center for Tobacco Products of the Food and Drug Administration (FDA) recently reviewed the website http://www.buycheaptobacco.net, and determined that the cigarette products listed are offered for sale to U.S. customers. Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. § 321(rr)), as amended by the Family Smoking Prevention and Tobacco Control Act, these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including cigarettes, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)).
FDA has determined that several of your products are adulterated under section 902(8) of the FD&C Act (21 U.S.C. § 387b(8)) because you promote them as modified risk tobacco products without an FDA order in effect that permits such promotion. You can find the FD&C Act through links on FDA’s homepage at http://www.fda.gov.
You describe products that you offer for sale on the website http://www.buycheaptobacco.net  as being “light” or “ultra-light” by referring to them as such in product advertising and adding the qualifiers  “Lights,” “Ultra-Lights,” to the product names. Specifically, our review of the website revealed that you offer for sale the following cigarettes described as “Lights”: Bond Special Selection, Camel Blue, Chesterfield Classic Blue, Davidoff Gold, Dunhill Fine Cut Dark Blue, Kent Futura No. 8, Lucky Strike Original Silver, Marlboro Gold, Pall Mall Blue, Parliament Aqua Blue, Winston Blue, Winston Super Slims Blue 100s, Magna Balanced Blue, More Balanced Blue, Sobranie Blue, Sobranie White Russian, and Viceroy Blue. Our review of your website revealed that you offer for sale the following cigarettes described as “Ultra-Lights”: Bond Fine Selection, Camel Silver, Chesterfield Classic Bronze, Davidoff Blue, Dunhill Fine Cut Azure, Kent Silver Neo No. 4, L&M Silver Label, Parliament Silver Blue, Vogue Super Slims Lilas 100s, Winston Silver, Camel Black Mini, Marlboro Silver, More Subtle Silver, Pall Mall Azure, Sobranie Gold, and Viceroy Silver.
A tobacco product with a label, labeling, or advertising that uses the descriptor “light,” “mild,” or “low,” or a similar descriptor, is a “modified risk tobacco product” under section 911(b)(2)(A)(ii) of the FD&C Act (21 U.S.C. § 387k(b)(2)(A)(ii)). Under section 911(a) of the FD&C Act (21 U.S.C. § 387k(a)), no person may introduce or deliver for introduction into interstate commerce any modified risk tobacco product without an FDA order in effect under section 911(g) of the FD&C Act (21 U.S.C. § 387k(g)). A product that is in violation of section 911(a) of the FD&C Act (21 U.S.C. § 387k(a)) is adulterated under section 902(8) of the FD&C Act (21 U.S.C. § 387b(8)). Because the website uses the descriptor “Light,” or similar descriptors for the above-listed products, the products are modified risk tobacco products.
Because these products are offered for sale to U.S. customers without an appropriate FDA order in effect under section 911(g) of the FD&C Act (21 U.S.C. § 387k(g)), these products are adulterated under section 902(8) of the FD&C Act (21 U.S.C. § 387b(8)).
You should immediately correct the violations stated above and take any necessary actions to bring your tobacco products into compliance with the FD&C Act. The violations discussed in this letter do not necessarily constitute an exhaustive list, and it is your responsibility to ensure that your tobacco products on this website, or any other websites you own, operate, and/or control, comply with the applicable provisions of the FD&C Act.
Failure to ensure full compliance with the FD&C Act may result in FDA initiating further action without notice, including, but not limited to, civil money penalties, no-tobacco-sale orders, criminal prosecution, seizure, and/or injunction. Please note that adulterated and misbranded tobacco products offered for importation into the United States are subject to detention and refusal of admission.
Please submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions, including the dates on which you discontinued the violative promotion, advertising, sale, and/or distribution of these tobacco products.
Please note your reference number, RW1200013, in your response and direct your response to the following address:
PAL-WL Response, Office of Compliance and Enforcement
FDA Center for Tobacco Products
9200 Corporate Boulevard
c/o Document Control Center
Rockville, Maryland 20850.
If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at Elenita.IbarraPratt@fda.hhs.gov.
Sincerely,
/S/
Ann Simoneau, J.D.
Director
Office of Compliance and Enforcement
Center for Tobacco Products
VIA UPS and Electronic Mail
cc:
buycheaptobacco.com@protecteddomainservices.com
compliance@protecteddomainservices.com
Name.com, LLC
2500 East Second Avenue, 2nd Floor
Denver, CO 80206
–
–

pharmacyathome.com

3 Comments

United States of America

The Ryan Haight Act Known as
Online Pharmacy Consumer Protection Act of 2008
Sec. 2. Requirement of a valid prescription for
 controlled substances dispensed by means of the Internet.

SUMMARY: The Ryan Haight Online Pharmacy Consumer Protection Act,
which was enacted on October 15, 2008,amended the Controlled Substances Act and Controlled Substances Import and Export Act by adding several new provisions to prevent the illegal distribution and dispensing of controlled substances by means of the Internet. DEA is hereby issuing an interim rule to amend its regulations to
implement the legislation and is requesting comments on the interim
rule


Address lookup
canonical name pharmacyathome.com
aliases
addresses 209.44.103.39
Domain Whois record

Queried whois.internic.net with “dom pharmacyathome.com”…

Domain Name: PHARMACYATHOME.COM
Registrar: DNC HOLDINGS, INC.
Whois Server: whois.directnic.com
Referral URL: http://www.directnic.com
Name Server: NS1.PHARMACYATHOME.COM
Name Server: NS2.PHARMACYATHOME.COM
Status: clientDeleteProhibited
Status: clientTransferProhibited
Status: clientUpdateProhibited
Updated Date: 09-aug-2011
Creation Date: 10-dec-2009
Expiration Date: 10-dec-2012

>>> Last update of whois database: Fri, 13 Jul 2012 19:56:12 UTC <<<

Queried whois.directnic.com with “pharmacyathome.com”…

Registrant:
Direct Privacy ID A7A3C
P.O. Box 6592
Metairie, LA 70009
US
1-504-355-0082

Domain Name: PHARMACYATHOME.COM

Administrative Contact:
Direct Privacy ID A7A3C, Domain Name Proxy Service, Inc pharmacyathome.com@domainnameproxyservice.com
P.O. Box 6592
Metairie, LA 70009
US
1-504-355-0082

Technical Contact:
Direct Privacy ID A7A3C, Domain Name Proxy Service, Inc pharmacyathome.com@domainnameproxyservice.com
P.O. Box 6592
Metairie, LA 70009
US
1-504-355-0082

Record last updated 08-09-2011 05:10:03 AM
Record expires on 12-10-2012
Record created on 12-10-2009

Domain servers in listed order:
NS1.PHARMACYATHOME.COM 209.44.103.39
NS2.PHARMACYATHOME.COM 209.44.103.38

The compilation, repackaging, dissemination, or other use of this WHOIS
data is expressly prohibited without the prior written consent of
DNC Holdings, Inc.

DNC Holdings reserves the right to terminate your access to its WHOIS
database in its sole discretion, including without limitation, for
excessive querying of the database or for failure to otherwise abide by
this policy.

DNC Holdings reserves the right to modify these terms at any time.

NOTE: THE WHOIS DATABASE IS A CONTACT DATABASE ONLY.
LACK OF A DOMAIN RECORD DOES NOT SIGNIFY DOMAIN AVAILABILITY.

Network Whois record

Queried rwhois.netelligent.ca with “209.44.103.39”…

%rwhois V-1.5:003eff:00 rwhois.netelligent.ca (by Network Solutions, Inc. V-1.5.9.5)
network:Class-Name:network
network:ID:NETEL-209.44.103.32-63
network:Auth-Area:209.44.103.0/27
network:Network-Name:NETELLIGENT-209.44.103.32-63
network:IP-Network:209.44.103.32/27
network:IP-Network-Block:209.44.103.32-63
network:Org-Name;I:Netelligent Hosting Services
network:City:Montreal
network:State:QC
network:Postal-Code:H4P 1P4
network:Country-Code:CA
network:Tech-Contact;I:support@netelligent.ca
network:Admin-Contact;I:admin@netelligent.ca
network:Updated-By:admin@netelligent.ca

%referral rwhois://root.rwhois.net:4321/auth-area=.
%ok

Queried whois.arin.net with “n 209.44.103.39″…

NetRange: 209.44.96.0 – 209.44.127.255
CIDR: 209.44.96.0/19
OriginAS: AS10929
NetName: NETEL-ARIN-BLK02
NetHandle: NET-209-44-96-0-1
Parent: NET-209-0-0-0-0
NetType: Direct Allocation
RegDate: 2006-08-01
Updated: 2012-03-02
Ref: http://whois.arin.net/rest/net/NET-209-44-96-0-1

OrgName: Netelligent Hosting Services Inc.
OrgId: NHS-31
Address: 1396 Franklin Drive
City: Laval
StateProv: QC
PostalCode: H7W-1K6
Country: CA
RegDate: 2005-03-09
Updated: 2012-03-01
Ref: http://whois.arin.net/rest/org/NHS-31

ReferralServer: rwhois://rwhois.netelligent.ca:4321

OrgAbuseHandle: NETEL2-ARIN
OrgAbuseName: Netelligent Abuse
OrgAbusePhone: +1-514-369-2209
OrgAbuseEmail: abuse@netelligent.ca
OrgAbuseRef: http://whois.arin.net/rest/poc/NETEL2-ARIN

OrgTechHandle: NETEL1-ARIN
OrgTechName: Netelligent Ops
OrgTechPhone: +1-514-369-2209
OrgTechEmail: ops@netelligent.ca
OrgTechRef: http://whois.arin.net/rest/poc/NETEL1-ARIN

RNOCHandle: NETEL-ARIN
RNOCName: Netelligent Admin
RNOCPhone: +1-514-369-2209
RNOCEmail: admin@netelligent.ca
RNOCRef: http://whois.arin.net/rest/poc/NETEL-ARIN

RTechHandle: NETEL1-ARIN
RTechName: Netelligent Ops
RTechPhone: +1-514-369-2209
RTechEmail: ops@netelligent.ca
RTechRef: http://whois.arin.net/rest/poc/NETEL1-ARIN

RAbuseHandle: NETEL2-ARIN
RAbuseName: Netelligent Abuse
RAbusePhone: +1-514-369-2209
RAbuseEmail: abuse@netelligent.ca
RAbuseRef: http://whois.arin.net/rest/poc/NETEL2-ARIN

DNS records

DNS query for 39.103.44.209.in-addr.arpa returned an error from the server: NameError
name class type data time to live
http://www.pharmacyathome.com IN CNAME pharmacyathome.com 14400s (04:00:00)
pharmacyathome.com IN MX
preference: 0
exchange: pharmacyathome.com
14400s (04:00:00)
pharmacyathome.com IN SOA
server: ns1.pharmacyathome.com
email: hakkamikka@gmail.com
serial: 2012012600
refresh: 86400
retry: 7200
expire: 3600000
minimum ttl: 86400
86400s (1.00:00:00)
pharmacyathome.com IN NS ns2.pharmacyathome.com 86400s (1.00:00:00)
pharmacyathome.com IN NS ns1.pharmacyathome.com 86400s (1.00:00:00)
pharmacyathome.com IN A 209.44.103.39 14400s (04:00:00)

— end —